U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07333430) titled 'Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma' on Dec. 30, 2025.
Brief Summary: A Phase 1a/1b Open-Label Study with Dose Escalation and Expansion Phases to Evaluate Safety and Preliminary Efficacy of Naive HBI0101 CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma.
Study Start Date: Jan. 15
Study Type: INTERVENTIONAL
Condition:
Relapsed/Refractory Multiple Myeloma (MM)
Intervention:
BIOLOGICAL: Naive HBI0101 CAR-T
Naive HBI0101 CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to...